Inhibitors of lysine specific demethylase-1
US-9573930-B2 · Feb 21, 2017 · US
Inhibitors of lysine specific demethylase-1
US10023543B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10023543-B2 |
| Application number | US-201715687251-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 25, 2017 |
| Priority date | May 1, 2014 |
| Publication date | Jul 17, 2018 |
| Grant date | Jul 17, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
First claim
Opening claim text (preview).
We claim: 1. A compound, or pharmaceutically acceptable salt thereof, chosen from: 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10023543B2 cover?
- The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are usefu…
- Who is the assignee on this patent?
- Celgene Quanticel Res Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D239/47. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).